Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- C0011777 label "dexamethasone" provenance.
- triple label "dexamethasone increased mortality" assertion.
- triple label "only dexamethasone and remdesivir shown To date" assertion.
- triple label "only dexamethasone and remdesivir be effective" assertion.
- triple label "multiple alternate dosing of NEPA ( netupitant / palonosetron ) without the addition of dexamethasone is highly effective for preventing nausea and vomiting in this difficult setting , with a good tolerability profile" assertion.
- triple label "The examples of results from trials studying dexamethasone and hydroxychloroquine for treatment of COVID-19 had contrasting outcomes, including the potential for significant numbers of lives saved with the early release of results from the RECOVERY trial studying dexamethasone contrasting with unsubstantiated data being presented from trials studying hydroxychloroquine" assertion.
- triple label "dexamethasone contrasting with unsubstantiated data being presented from trials studying hydroxychloroquine" assertion.
- triple label "dexamethasone have a better result in hospitalized patients , especially in low - resources settings" assertion.
- triple label "dexamethasone ( Dex ) bind to both the viral and host receptors as a potential drug candidate for COVID-19" assertion.
- triple label "dexamethasone ( Dex ) could bind to both the viral and host receptors as a potential drug candidate for COVID-19" assertion.
- triple label "several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir used because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" assertion.
- triple label "Thirty - three patients ( 21.9 % ) in the dexamethasone group vs 43 ( 29.1 % ) in the standard care group experienced secondary infections" assertion.
- triple label "intravenous dexamethasone increases the number of ventilator - free days among patients with COVID-19 - associated ARDS" assertion.
- triple label "use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator - free days ( days alive and free of mechanical ventilation ) over the first 28 days" assertion.
- triple label "use of intravenous dexamethasone plus standard care compared with standard care alone" assertion.
- triple label "A regimen of hydroxychloroquine , azithromycin , and dexamethasone initiated in 3 severe cases of COVID-19 pneumonia in cruise ship employees who were admitted to the ICU and responded to supportive mechanical ventilation and pulmonary hygiene management" assertion.
- triple label "A regimen of hydroxychloroquine , azithromycin , and dexamethasone initiated in 3 severe cases of COVID-19 pneumonia in cruise ship employees who were admitted to the ICU and responded to supportive mechanical ventilation and pulmonary hygiene management" assertion.
- triple label "Although the anti - inflammatory corticosteroid dexamethasone 's administration for viral infection managing is controversial is increasing evidence demonstrating that the anti - inflammatory corticosteroid dexamethasone treatment is capable of drastically diminishing the death rate of patients presenting with Acute Respiratory Distress Syndrome ( ARDS ) that required invasive mechanical ventilation" assertion.
- triple label "the anti - inflammatory corticosteroid dexamethasone treatment is capable of drastically diminishing the death rate of patients presenting with Acute Respiratory Distress Syndrome ( ARDS ) that required invasive mechanical ventilation" assertion.
- triple label "the anti - inflammatory corticosteroid dexamethasone treatment diminishing the death rate of patients presenting with Acute Respiratory Distress Syndrome ( ARDS ) that required invasive mechanical ventilation" assertion.
- triple label "the anti - inflammatory corticosteroid dexamethasone being deleterious for diabetics and hypertensive patients , two major COVID-19 risk groups" assertion.
- triple label "the anti - inflammatory corticosteroid dexamethasone inducing hyperglycemia and sodium retention" assertion.
- triple label "the anti - inflammatory corticosteroid dexamethasone impairing viral clearance" assertion.
- triple label "the anti - inflammatory corticosteroid dexamethasone taking into consideration underlying medical conditions and COVID-19 disease severity" assertion.
- triple label "dexamethasone be effective in patients in need of respiratory assistance" assertion.
- triple label "visual acuity outcomes to topical prednisolone acetate the dexamethasone intracanalicular insert is an appropriate means of postoperative symptom control in this quality of life - conscious population" assertion.
- triple label "the dexamethasone intracanalicular insert produced comparable ocular comfort , corneal staining" assertion.
- triple label "Low - dose dexamethasone therapy is the best therapeutic approach" assertion.
- triple label "Remdesivir , dexamethasone , azithromycin , favipiravir , lopinavir / ritonavir , atazanavir , hydroxychloroquine , interferon beta , ribavirin , tocilizumab , anakinra and sarilumab identified as experimental drugs being used in the associated coronavirus disease 2019 ( COVID)-19 ) trials as of November 2020" assertion.
- triple label "dexamethasone or other corticosteroids and IL-6 inhibitors including sarilumab , tocilizumab , and siltuximab" assertion.
- triple label "either methylprednisolone or dexamethasone associated with increased survival in COVID-19 patients at risk of hyper - inflammatory response" assertion.